The GLP is committed to full transparency. Download and review our Annual Report.

Google shoots and misses with biotech innovations

| | June 10, 2016

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion and analysis.

Google employees, squeezed onto metal risers and standing in the back of a meeting room, erupted in cheers as newly arrived executive Andrew Conrad announced they would try to turn science fiction into reality: The tech giant had formed a biotech venture to create a futuristic device like Star Trek’s iconic “Tricorder” diagnostic wizard — and use it to cure cancer.

Conrad, recalled an employee who was present, displayed images on the room’s big screens showing nanoparticles tracking down cancer cells in the bloodstream and flashing signals to a Fitbit-style wristband. He promised a working prototype of the cancer early-detection device within six months.

That was three years ago. Recently departed employees said the prototype didn’t work as hoped, and the Tricorder project is floundering. But Tricorder is not the only misfire for Google’s ambitious and extravagantly funded biotech venture, now named Verily Life Sciences.

Read full, original post: ‘Silicon Valley arrogance’? Google misfires as it strives to turn Star Trek fiction into reality

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend